Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc has a market capitalization of $19.52 million and a price-to-book ratio of 0.23, indicating a significant discount to its book value. The company's liquidity position is strong, with a current ratio of 6.75 and $17.91 million in cash and equivalents, which is a positive signal for short-term financial stability.

The company's profitability metrics are negative, with a return on equity of -12.34% and a return on assets of -10.89%, which are below the industry norms for biotechnology firms. The operating cash flow of -$22.29 million and free cash flow of -$10.57 million indicate that the company is not generating positive cash from operations and is likely relying on financing activities to sustain operations.

Citius Pharmaceuticals Inc does not report segment or geographic revenue data in the provided financial snapshot, which limits the ability to assess revenue concentration or geographic exposure. However, the absence of long-term debt and a debt-to-equity ratio of 0.0 suggest that the company is not leveraging debt to finance operations, which may be a conservative approach in a capital-intensive industry.

The company's growth trajectory is uncertain, as the financial data does not provide forward-looking revenue projections. The negative operating and net income figures suggest that the company is not yet profitable and may require continued investment to develop its pipeline of therapies. The lack of positive cash flow from operations also raises questions about the company's ability to sustain operations without external financing.

The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and lack of profitability could increase the likelihood of future dilution if additional capital is required. The absence of long-term debt is a positive factor, but the company's reliance on cash reserves may limit its flexibility in the long term.

Recent events, as reflected in the financial data, show that the company has not issued new shares or raised additional capital in the most recent reporting period. The analyst estimates suggest a mean price target of $6.00, which is significantly higher than the current market price of $0.72, indicating potential upside if the company can achieve profitability and positive cash flow.

Analysts project 990.9% upside to a $6.00 target price, signaling strong potential for significant share price appreciation.

The company maintains a low leverage band with a debt-to-equity ratio of 0.1028, indicating a conservative capital structure.

Citius Pharmaceuticals exhibits best-in-class cash conversion metrics compared to the biotechnology cohort median, suggesting efficient capital management.

The firm carries minimal long-term debt of $1 million as of fiscal year 2025, reducing fixed financial obligations.

The company generated zero revenue across all reported fiscal years from 2021 to 2025, indicating a complete lack of commercial sales.

Net losses widened to $39.1 million in fiscal year 2024, reflecting persistent and growing operational unprofitability.

Free cash flow turned negative by $44.4 million in fiscal year 2024, highlighting significant cash burn and liquidity consumption.

Operating income deteriorated to a $39.6 million loss in fiscal year 2024, showing worsening core operational performance.

Revenue $3.9M; Operating income +10,2% YoY.

• ▍Revenue $3.9M
• ▍Operating income +10,2% YoY
• ▍Net income +15,8% YoY
• ▍Free cash flow −29,3% YoY
• ▍Net margin -208.4%

Revenue $0.00; Operating income +23,6% YoY.

• ▍Revenue $0.00
• ▍Operating income +23,6% YoY
• ▍Net income +26,2% YoY

Revenue $0.00; Operating income +17,4% YoY.

• ▍Revenue $0.00
• ▍Operating income +17,4% YoY
• ▍Net income +16,9% YoY

Revenue $0.00; Operating income -$11.3M.

• ▍Revenue $0.00
• ▍Operating income -$11.3M

Revenue $0.00; Operating income -$10.0M.

• ▍Revenue $0.00
• ▍Operating income -$10.0M

Revenue $0.00; Operating income -$11.1M.

• ▍Revenue $0.00
• ▍Operating income -$11.1M

Revenue $0.00; Operating income -$10.6M.

• ▍Revenue $0.00
• ▍Operating income -$10.6M

Revenue $0.00; Operating income +2,7% YoY.

• ▍Revenue $0.00
• ▍Operating income +2,7% YoY
• ▍Net income +4,4% YoY

Revenue $0.00; Operating income −19,5% YoY.

• ▍Revenue $0.00
• ▍Operating income −19,5% YoY
• ▍Net income −20,3% YoY
• ▍Free cash flow −36,5% YoY

Revenue $0.00; Operating income +0,5% YoY.

• ▍Revenue $0.00
• ▍Operating income +0,5% YoY
• ▍Net income +3,3% YoY
• ▍Free cash flow +3,3% YoY

Revenue $0.00; Operating income −42,6% YoY.

• ▍Revenue $0.00
• ▍Operating income −42,6% YoY
• ▍Net income −45,9% YoY
• ▍Free cash flow +46,7% YoY